Onpode
Cover art for A pill taken before breakfast slashed bad cholesterol by nearly two-thirds in patients already on statins

A pill taken before breakfast slashed bad cholesterol by nearly two-thirds in patients already on statins

November 22, 2026 · 9 min

Iris Holm & Cyrus Reed

Enlicitide (Lipfendra), FDA-approved July 16, 2026, is the first oral PCSK9 inhibitor — a once-daily pill that cut LDL cholesterol by up to 65% in statin users during Merck's Phase 3 CORALreef trial. No cardiovascular outcomes data yet exists; that trial is ongoing.

On November 21, 2026, clinical trial data on enlicitide (brand name Lipfendra) were presented at the American Heart Association (AHA) Scientific Sessions 2026 in Chicago. Developed by Merck & Co. (MSD), enlicitide is a once-daily oral proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor — the first oral agent in a drug class previously available only via injection.

0:008:34
Get the next episode on Health →

Follow it free — new episodes land in your feed.

Or make your own — any topic, in minutes

More Onpode episodes on Health →

About this episode

A once-daily pill just became the first oral PCSK9 inhibitor — a class of drugs that until now required injections and, more often than not, a fight with an insurer. In Merck's Phase 3 CORALreef trial, enlicitide cut LDL cholesterol by roughly 65 percent in patients already taking statins, outpacing every oral comparator tested. The FDA approved it in July 2026. On paper, that's a landmark. But this episode doesn't let the number stand alone. It digs into why a spectacular drop in a blood marker doesn't automatically mean fewer heart attacks — and what we already know about that gap. Evolocumab cut LDL by 59 percent; events fell by about 15 percent relative over two years. Pelacarsen cut Lp(a) by 78 percent and missed its primary endpoint entirely. LDL-C is a surrogate, a proxy, and the outcomes trial for enlicitide hasn't reported yet. The episode also asks whether a pill actually solves the access problem that made the injectables underused for years. If the price and the prior-authorization rules stay the same, a tablet is just a smaller needle. That's not a small thing to sit with. What you're left with: a genuinely promising molecule, a mechanism with strong genetic backing, two years of sustained LDL reduction in extension data — and an outcomes trial that will eventually answer whether any of it translates to longer lives. Worth knowing where the evidence actually stops.

Frequently asked

What is Lipfendra and how does it lower cholesterol?

Lipfendra (enlicitide), FDA-approved July 16, 2026, is the first oral PCSK9 inhibitor. It blocks the PCSK9 protein that destroys LDL receptors in the liver, allowing more receptors to recycle and pull LDL cholesterol out of the bloodstream — without injections.

How much does enlicitide lower LDL cholesterol?

In Merck's Phase 3 CORALreef trial, enlicitide lowered LDL cholesterol by approximately 65% at eight weeks in patients already on statins. A pooled 24-week analysis in the Annals of Pharmacotherapy confirmed a sustained range of 57.1–64.6%, compared to roughly 28% for ezetimibe.

Has enlicitide been proven to reduce heart attacks or strokes?

Enlicitide has not yet been proven to reduce heart attacks or strokes. As of late 2026, only LDL-lowering data exist; the cardiovascular outcomes trial is ongoing. The Lp(a) drug pelacarsen cut its biomarker 78% but missed its primary outcomes endpoint, illustrating why surrogate markers can mislead.

Why were injectable PCSK9 inhibitors underused if they worked?

Injectable PCSK9 inhibitors like evolocumab were underused primarily due to high cost and prior authorization barriers — not patient reluctance or clinical doubts. A pill format may improve convenience, but analysts note that payer denial letters and pricing rules would need to change for access to meaningfully improve.

How does an oral PCSK9 inhibitor survive digestion?

Enlicitide is a macrocyclic peptide — a ring-shaped molecule more resistant to stomach acid than a linear peptide chain. It also uses a decanoate permeation-enhancer formulation to cross the gut lining, a strategy analogous to the SNAC technology used in oral semaglutide.

Grounded in 6 sources
Evaluating enlicitide decanoate: first oral PCSK9 inhibitor for the treatment of adults with hypercholesterolemia ↗ · doi.org
Enlicitide: The First Oral PCSK9i for Lowering Low-Density Lipoprotein Cholesterol ↗ · doi.org
Oral PCSK9 inhibitors for elevated LDL-C: A systematic review and meta-analysis of randomized trials ↗ · pmc.ncbi.nlm.nih.gov
Inflammation and lipid-related determinants in coronary atherosclerosis: mechanisms, biomarkers, and therapeutic implications ↗ · frontiersin.org
New review of the first oral PCSK9 drug, a needle-free option for high cholesterol - Medical Xpress ↗ · medicalxpress.com
Oral PCSK9 Inhibitors Cut LDL Cholesterol by Fifty-Eight Percent in ↗ · bioengineer.org
Read transcript

Iris Holm: Hey, I'll admit I walked in skeptical, and you look far too pleased about a pill.

Cyrus Reed: Because it's a pill, that's the point! Okay, wait, picture a Tuesday, 7:15, coffee maker gurgling, and a 58-year-old with one stent. LDL 92 on atorvastatin, over goal. He swallows one extra tablet. That's the whole scene, and it used to need a fridge and a pen.

Iris Holm: Mechanism. Plain English. Go.

Cyrus Reed: Right, so the liver has catchers, little hooks grabbing cholesterol out of blood. A protein, PCSK9, keeps dumping catchers in the trash, so there are fewer of them. Block that protein and catchers get recycled, and more cholesterol gets pulled out. That's all it is.

Iris Holm: Huh. So the pill doesn't touch the cholesterol itself.

Cyrus Reed: No, it saves the catchers. Enlicitide, Lipfendra, FDA-approved July 16, 2026, the first oral PCSK9 inhibitor.

Iris Holm: Saved catchers, fine. So the mechanism was never the hard part. The hard part was getting it past the stomach. Then the trial. Merck's Phase 3 CORALreef, head-to-head, everyone on statins already. What happened?

Cyrus Reed: Okay, so March 30th, 2026, Merck, MSD, puts out a release. At eight weeks, enlicitide beats bempedoic acid, beats ezetimibe, beats the two of them together, all added on top of background statins. And the numbers, wait, they're not close. About 65 percent LDL drop. Ezetimibe, about 28. Bempedoic acid, about 6.

Iris Holm: Six.

Cyrus Reed: Six! And a pooled analysis in the Annals of Pharmacotherapy, 24 weeks, lands at 57.1 to 64.6 percent. So it's not one lucky trial, it's a range that holds. Different weight class.

Iris Holm: Hold on. Antibodies and siRNA stayed injectable for a reason. Peptides get shredded in the gut. What's the trick?

Cyrus Reed: It's a macrocyclic peptide, a ring, sturdier than a floppy chain, plus permeation enhancers, a decanoate formulation, that loosen the gate just enough to slip across. Wait, that's, is that the same move as oral semaglutide? Where SNAC helps it absorb? Because if so, this isn't a cholesterol story, it's a platform story. What else is stuck behind that door?

Iris Holm: Maybe. But look at what we've actually watched. A blood number. LDL, at eight weeks, at 24 weeks. Statins stay the foundation, this is an add-on. And no one has shown fewer heart attacks yet. That gap bothers me.

Cyrus Reed: But that gap, wait, it's not hypothetical, is it? Something already fell into it. Pelacarsen, the Lp(a) drug. Lp(a)HORIZON. It cut Lp(a) by 78 percent, and, how do I even say this, the events came out 12.3 percent versus 12.1 on placebo.

Iris Holm: Primary endpoint missed. Seventy-eight percent, and nothing moved.

Cyrus Reed: Nothing! So how do I know 65 percent LDL isn't the same trap? I mean, the EAS put out a statement November 15th, still calling Lp(a) an independent risk modifier, and the National Lipid Association said keep researching. Nobody's walking away from the target.

Iris Holm: Right. Because LDL-C is a surrogate. A proxy. Not a heart attack, not a stroke, not death. Why would this proxy behave better?

Cyrus Reed: Okay, because LDL has the genetics. About 312,000 people, and lifelong lower LDL cuts risk roughly three times more than lowering it late. So that's, huh, that's a different kind of target. Decades of plaque is the mechanism.

Iris Holm: Fine. Then LDL is probably causal. Does that make this molecule work?

Cyrus Reed: No. Wait, no, that's the exact seam. "LDL is causal" is not the same claim as "this drug works." Off-target stuff, a different population, I can't wave that away. And enlicitide's outcomes trial is ongoing. Nothing reported.

Iris Holm: Then here's what bothers me. Injectable evolocumab, FOURIER. LDL down about 59 percent. Events down about 15 percent relative, over roughly two years.

Cyrus Reed: Fifteen? That's it? I assumed it'd track closer.

Iris Holm: A huge drop bought a modest benefit. So the ceiling may already be known. And the two-year extension data, and the injectables' underuse, change what we should expect. We'll get there.

Cyrus Reed: Fifteen percent, yeah, and that's exactly why the two-year number nags me. November 21st, Chicago, AHA Scientific Sessions. Christie Ballantyne, Baylor College of Medicine, presents the CORALreef Extension interim. LDL-C still down at 104 weeks. ApoB down, Lp(a) down, triglycerides, non-HDL-C, all of it.

Iris Holm: Open-label. Everyone knew they were on the drug.

Cyrus Reed: Sure, and Merck ran it, I'm not waving that off. But picture the artery. LDL particles slip under the lining, they oxidize, the immune cells show up, and plaque builds. Silent. Thirty years before the first chest pain. So two years is, wait, it's like judging a mortgage by the first two payments.

Iris Holm: Then give me your strongest case. Why isn't waiting for hard endpoints negligence?

Cyrus Reed: Oh, that's my line! Okay. Because the man with the stent doesn't have thirty years of waiting. Every year at 92 is another year of plaque, and the outcomes trial hasn't reported. Waiting sounds careful, but, I mean, it's also a decision.

Iris Holm: It's a decision with a cost on both sides. Pelacarsen was also a decision. Two years shows LDL stays down. Not that anyone lives longer. And the Journal of Clinical Lipidology review, November 20th, says positioning hinges on outcomes, adherence, access, long-term safety.

Cyrus Reed: Access. Huh. Okay, here's my surprise. Injectable PCSK9 inhibitors already did this. Potent, proven to lower LDL, and they sat underused for years. Cost, prior authorization. So the molecule was never the bottleneck.

Iris Holm: Hold on. Then the pill fixes the pen, not the denial letter.

Cyrus Reed: The pen, yeah, not the letter. And wait, I keep picturing him at the coffee maker, pillbox open, and nobody in that kitchen knows who approves what. He's just the guy whose LDL is over 70.

Iris Holm: Right. Over goal on a statin. Twice, prior authorization for an injectable came back denied. Now the cardiologist writes for a tablet. Does the payer read it differently?

Cyrus Reed: Honestly? I don't know. If the price is the same and the rules are the same, then it's the same letter.

Iris Holm: Same denial, smaller needle. Price and coverage rules have to move, not just the format. A tablet doesn't change a spreadsheet.

Cyrus Reed: Huh. And then it splits. If the outcomes trial confirms benefit, the whole question becomes access, who gets it, and how fast. But if it comes back neutral, like pelacarsen with its 78 percent and its 12.3 versus 12.1, then it's a lesson about what a biomarker can actually promise. Either way the pill is real. It's just not proof yet.

Iris Holm: Real, not proof. I can sit with that.

Cyrus Reed: Me too. Though I'll admit I'm still hoping his 7:15 tablet turns out to matter, quietly, over thirty years of Tuesdays.